dipraglurant ER (ADX-48621 ER) / Addex - LARVOL DELTA

Addex Provides trading update and completes 2019 with cash position of CHF31.5 million (GlobeNewswire, Addex Therapeutics) - "Addex Therapeutics...today announced that it completed 2019 with CHF31.5 million of cash and cash equivalents, and in 2019 used net cash in operations of CHF10.2 million....Our financial performance in 2019 was driven by spending on our dipraglurant Parkinson’s disease levodopa induced dyskinesia (PD-LID) program....Dipraglurant: registration program on track to start first pivotal registration study in Q1 2020 for the treatment of dyskinesia associated with Parkinson’s disease."

Commercial • New trial

Van Leeuwenhoeck issues equity research report (GlobeNewswire) - "Addex Therapeutics...today announced that...Van Leeuwenhoeck, has issued an equity research report...Analyses in the report notes a significant undervaluation of Addex, which is trading currently at CHF1.60 per share, as well as key value drivers including the start of a pivotal registration study of dipraglurant for levodopa-induced dyskinesia associated with Parkinson’s disease in Q1 2020....'Other in-house discovered programs is likely to drive significant share price appreciation in the coming 12 months...'"

Financing • New trial

Addex increases issued share capital and creates treasury shares (GlobeNewswire) - "Addex Therapeutics...today announced that it has increased its capital from 28,564,031 to 32,848,635 through the issue of 4,284,604 new registered shares at a nominal value of CHF1 each to Addex Pharma S.A....'This transaction has been executed to provide us with future financing flexibility as we execute on our plans to start a pivotal registration study with dipraglurant in Parkinson’s disease levodopa-induced dyskinesia (PD-LID) by the end of 2019,' said Tim Dyer, CEO of Addex. 'This is purely a preparatory step and we have no intention of using these new shares...'"

Financing • New trial